European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Trials

2024-515163-63-00

EU Clinical Trials Information System

Trial ID
T-ctis-2024-515163-63-00
Registry
EU Clinical Trials Information System
CTIS number
2024-515163-63-00
Asset
psilocybin (investigator-led)
Sponsor, as registered
Region Skane
Phase
Therapeutic exploratory (Phase II)
Indication
Anorexia Nervosa
Status
Authorised
Start date
16/12/2025
Primary completion
CTIS does not publish one.
Member states concerned
Sweden
Sites
1

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-10-19

Notes on the record

Supersedes the T-ctis-2024-515163-63-00 row verified 2026-08-31. Changed: start_date (empty) -> 16/12/2025. trialEvents SE START_OF_TRIAL 2025-12-16, START_OF_RECRUITMENT 2026-01-27, both first visible on the public record published 2026-10-17 (recorded 2026-10-16); ctPublicStatusCode 2 -> 4 (verbatim, not decoded). Fields read from the CTIS public API retrieve record on 2026-10-19 17:32 CEST (publishDate 2026-10-17T03:40); site_count is the sum of trialSites across authorizedPartsII; codes not decoded; no primary completion date published.

Company

Through psilocybin (investigator-led): Region Skane

Cited in

Issues quoting 2024-515163-63-00 in their own text.

Record history